ID
14136
Beschrijving
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583
Trefwoorden
Versies (1)
- 31-03-16 31-03-16 -
Houder van rechten
CC BY-NC 3.0
Geüploaded op
31 maart 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
VX-950HPC3006 NCT01571583 Final rash/cutaneous event evaluation
VX-950HPC3006 NCT01571583 Final rash/cutaneous event evaluation
- StudyEvent: ODM
Similar models
VX-950HPC3006 NCT01571583 Final rash/cutaneous event evaluation
- StudyEvent: ODM
C1880274 (UMLS CUI [1,2])
C0237753 (UMLS CUI [1,2])
C0035173 (UMLS CUI [1,2])
C0259831 (UMLS CUI [1,2])
C0259831 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])